MedTrace Logo

Bemiparin as a Thromboprophylaxis After Gynaecological Surgeries

NCT01630148 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 774

Last updated 2024-09-19

No results posted yet for this study

Summary

The use of prophylaxis for venous thromboembolism (VTE) remains grossly underused for women who undergo gynecologic surgery for benign conditions world wide and especially in developing countries including our region. Having a research in our locality for the first time might raise awareness of the importance of VTE prophylaxis.

Conditions

Interventions

DRUG

Bemiparin

Bemiparin Sodium 3,500IU anti Xa/0.3 ml solution for injection in pre-filled syringe will be provided for each patient in Bemiparin group (Moderate, High and Highest risk groups for thromboembolism) 6 hours after surgery and then daily for up to 7 days.

Sponsors & Collaborators

  • Hawler Medical University

    lead OTHER

Principal Investigators

  • Shahla K. Alalaf, M.D · Hawler Medical University

  • Ariana K. Jawad, C.A.B.OG · Hawler Ministry of Health

  • Rojan K. Jawad, Diploma · Hawler Medical University

  • Mahabad S. Ali, Diploma · Hawler Ministry of Health

  • Namir G. Al Tawil, Professor · Hawler Medical University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
90 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • Iraq

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01630148 on ClinicalTrials.gov